The CLL Society Tribune: full of research, news, advice, art and sharing

[bkoffman]

Heading home from lecturing in Germany. Very proud of this quarter's CLL Society Tribune: cllsociety.org/quarter-2-20... this quarter. I have an interview with Dr. Shanafelt, the lead on the ECOG trial that showed the superiority of Ibrutinib over FCR in nearly all frontline settings, plus wonderful sharing from patients and caregivers and so much more. Please take a look.

Stay strong. We are all in this together

Brian

[studebaker]

Thank you for educating and sharing👍

Dana

[bkoffman CLL CURE Hero in reply to studebaker]

Thanks.

[Jackpot]

What a great resource. Thank you so much for bringing it to our attention. Lots of information.

[bkoffman CLL CURE Hero in reply to Jackpot]

Thanks. We are always looking for patients and caregivers too write and share, so if you want to jump in, please reach out at [e-mail]

[DaveGH]

Thank you for sharing. These stories hit home for me right now.

Dave

[bkoffman CLL CURE Hero in reply to DaveGH]

Thanks. Glad we could be timely for you. Please consider writing for us. Just contact [e-mail]. Thanks Stay strong. We are all in this together. Brian